drugset / Trial / NCT07158398
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
NaSequentialOpen-labelBasic science
Summary
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
Timeline
- Start
- 2025-10-31
- Primary completion
- 2025-12-08
- Completion
- 2025-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | — | Oral |
| Subject | Vimseltinib | Small molecule | — | Oral |
Indications
No indication recorded.